| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Revenues | 730,571 | 353,375 | 511,283.25* | |
| Cost of revenues | 425,844 | 290,491 | 360,148* | |
| Gross profit | 304,727 | 62,884 | 151,135.25* | |
| Sales, general and administrative | 1,291,318 | 1,352,758 | 835,710.75* | |
| Research and development | 257,632 | 153,482 | 148,142.25* | |
| Total operating expenses | 1,548,950 | 1,506,240 | 983,853* | |
| Operating loss | -1,244,223 | -1,443,356 | -832,717.75* | |
| Interest expense | 272,245 | 267,008 | 39,051.75* | |
| Interest income | 14,476 | 6,653 | 5,349.75* | |
| Loss on change in fair value of warrant liability | - | -148,766 | 1,934.25* | |
| Loss on issuance of convertible note | -4,236 | -322,359 | -70,191* | |
| Other expense, net | -115 | - | -28.75* | |
| Total other (expense) income | -262,120 | -731,480 | -101,987.5* | |
| Net loss | -1,506,343 | -2,174,836 | -934,705.25 | |
| Deemed dividend on warrant modifications | 1,124,676 | - | - | |
| Preferred stock dividends | 121,662 | -54,192 | - | |
| Net loss attributable to common stockholders | -2,752,681 | -2,120,644 | - | |
| Basic EPS | -0.26 | -0.28 | -0.19 | |
| Diluted EPS | -0.26 | -0.28 | -0.19 | |
| Basic Average Shares | 10,790,722 | 7,657,229 | 4,930,287 | |
| Diluted Average Shares | 10,790,722 | 7,657,229 | 4,930,287 | |
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)